Latest Financial Performance News

Euroz Hartleys Group Limited reported a robust half-year result for December 2025, with net profit more than doubling to $13.84 million, driven by strong growth in equity capital markets and advisory fees.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Wagners Holding Company Limited has reported a robust half-year result for December 2025, with revenue climbing to $251.7 million and net profit after tax soaring 70% to $21 million. Improved margins and operational efficiencies across key segments underpin the strong performance.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.

CVC Limited posted a $6.7 million net loss for the half-year ended December 2025, driven by project delays and absent property sales, while strengthening liquidity through refinancing.

Papyrus Australia Limited reported a reduced half-year loss and marked a significant commercial milestone with a $4.2 million supply contract, advancing its transition from technology development to early-stage commercialisation.

SIV Capital Limited reported a 29.7% increase in its half-year loss to $172,763, with revenue down 41%, while its ASX suspension continues as it pursues a confidential transaction to regain listing status.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Aeris Resources has reported a robust half-year performance with a 62% jump in profit, a successful $101.6 million equity raise, and a strategic divestment of North Queensland assets. The company also announced plans to acquire Peel Mining’s South Cobar Copper Project, signaling an aggressive growth trajectory.

Scentre Group reported robust 2025 results with a 4.9% rise in Funds From Operations and record customer visitation, while progressing key sustainability and growth initiatives.